Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Fibrolamellar hepatocellular carcinoma 1Carcinoma, Hepatocellular 1Blast Crisis 1

Interventions

Cyclophosphamide 5nilotinib 4Cytarabine 4fludarabine 3Methotrexate 3Imatinib Mesylate 3Dasatinib 3Busulfan 3fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2AP 1903 reagent 2sargramostim 1ruxolitinib 1merphos 1amsonic acid 1Whole-Body Irradiation 1Vincristine 1Valproic Acid 1Thiotepa 1Tacrolimus 1Sirolimus 1Saline Solution 1Rituximab 1Prednisone 1Ondansetron 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Mesna × Clear all
NCT01670084 2015-10-30

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Mayo Clinic

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡